Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/clc.2005.s.010 | DOI Listing |
Publication Analysis
Top Keywords
lung cancer
12
non-small-cell lung
8
bortezomib-based combinations
4
combinations treatment
4
treatment non-small-cell
4
cancer lung
4
cancer common
4
common cancer-related
4
cancer-related death
4
death men
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!